24/7 Market News Snapshot 05 February, 2025 – Oragenics Inc. (NYSE:OGEN)

February 5, 2025

DENVER, Colo., 05 February, 2025 (247marketnews.com) – (NYSE:OGEN) are discussed in this article.
Oragenics Inc. is experiencing a remarkable surge in investor interest, as evidenced by a notable pre-market increase in its stock price, which rose by 70.71% to reach $0.485, up from the previous close of $0.284. This substantial uptick is accompanied by a robust trading volume of 52.14 million shares, capturing significant attention from traders and analysts alike, and suggesting a potential market breakout for the company.

In a complementary development, Dr. James P. Kelly, Oragenics’ Chief Medical Officer, is set to participate as a distinguished panelist at the 12th Annual Brain Health Summit scheduled for February 8, 2025. This summit, occurring alongside the Super Bowl celebrations, aims to advance awareness and enhance treatment options for athletic concussions and traumatic brain injuries (TBIs). Dr. Kelly, recognized for his expertise in neurology and concussion management, will engage with fellow industry leaders to explore the long-term effects of TBIs and promote innovative treatment strategies.

Dr. Kelly expressed his enthusiasm for participating in this significant event, emphasizing Oragenics’ commitment to confronting the challenges associated with brain injuries. He highlighted ONP-002, an intranasal neurosteroid specifically designed to address the urgent needs in concussion treatment. Dr. Kelly noted that conferences of this nature are crucial for fostering collaboration and advancing methodologies such as neuroplasticity and novel delivery systems, thereby enhancing care in the field of brain health.

The summit, hosted by renowned sports agent Leigh Steinberg—a prominent advocate for player safety—will serve as a crucial forum for medical professionals, ex-athletes, and industry innovators to drive progressive change in brain health standards. With Dr. Nicole Roberts moderating the discussions, the event promises to bring forth significant insights into enhancing neurological healthcare. As Oragenics undertakes these pivotal initiatives, it remains steadfast in its mission to develop solutions that significantly improve the lives of individuals affected by TBIs.

Related news for (OGEN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.